No Data
No Data
No Data
Jinhe Biotech (002688.SZ) has repurchased 1.62% of its shares at a cost of about 38.74 million yuan
Zhitong Finance App News, Jinhe Biotech (002688.SZ) issued an announcement. As of April 30, 2024, the company had repurchased a total of 12.6538 million shares through a special securities repurchase account, accounting for 1.62% of the company's total share capital. The highest transaction price was 3.27 yuan/share, the minimum transaction price was 2.92 yuan/share, and the total transaction amount was 38.74 million yuan.
Jinhe Biotech (002688.SZ): The company has full confidence in the overall business situation and achievement of performance indicators in 2024
Gelonghui May 7 丨 Jinhe Biotech (002688.SZ) Investor Relations Activity Record Sheet shows that the company's revenue did not increase year-on-year in the first quarter, mainly due to the fact that the downstream aquaculture industry was still sluggish, and the first quarter was relatively low season for the industry. In 2024, the company formulated the 2024 financial budget plan based on reasonable predictions and judgments on the economic situation and upstream and downstream industries. We believe that upstream raw materials and energy prices are still on a downward trend, pig prices are expected to continue to rise, and the downstream farming industry is expected to break out of the slump. The company's new chemicals and vaccines (doxycycline, vaccine) will receive incremental revenue
Jinhe Biotechnology CO., LTD.'s (SZSE:002688) Market Cap up CN¥430m Last Week, Benefiting Both Individual Investors Who Own 51% as Well as Insiders
Key Insights Significant control over Jinhe Biotechnology by individual investors implies that the general public has more power to influence management and governance-related decisions A total of 2
Jinhe Biotech (002688.SZ): 2023 net profit of 86.457 million yuan increased 14.34% year-on-year
On April 28, Gelonghui Biotech (002688.SZ) released its 2023 annual report. The revenue for the reporting period was 2.174 billion yuan, an increase of 2.42% over the previous year. Net profit attributable to shareholders of listed companies was 86.457 million yuan, an increase of 14.34% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 779.329 million yuan, an increase of 12.76% over the previous year. Basic earnings per share were $0.1108. It is proposed to distribute a cash dividend of 1.00 yuan (tax included) for every 10 shares to all shareholders.
Jinhe Biotech (002688.SZ) has repurchased a total of 1.62% of its shares at a cost of 387.437 million yuan
Jinhe Biotech (002688.SZ) announced that as of March 31, 2024, the company will use centralized bidding transactions...
Jinhe Biology (002688.SZ): The veterinary chemical kinomycin can be used to treat diseases such as respiratory, urinary tract, skin and soft tissue infections in livestock and poultry
Gelonghui, April 2 | Jinhe Biology (002688.SZ) said on the investor interactive platform that the company's veterinary chemical, cinnamomycin, can be used to treat diseases such as respiratory, urinary tract, and skin and soft tissue infections in livestock and poultry. It can also improve feed utilization, shorten the fattening period, and increase survival rate. The company currently has 16 vaccine products, including pig vaccines (porcine blue ear, porcine mycoplasma, pig round, pig round ring, pig foot-and-mouth disease, stomach and stomach duality), ruminant vaccine (bovine sheep disease), pet vaccine (rabies vaccine), etc.
No Data